FAQs

What differentiates ASCO AI in Oncology from The ASCO Post? 

While The ASCO Post covers topics of artificial intelligence within its overall coverage of oncology news, ASCO AI in Oncology is solely focused on bringing you coverage of news and research related to artificial intelligence use in oncology practice, allowing for broader as well as more in-depth views of topics relating to the challenges and opportunities in this evolving field. 

Is ASCO AI in Oncology written by the American Society of Clinical Oncology team and members? 

ASCO AI in Oncology was created by Conexiant in partnership with the American Society of Clinical Oncology (ASCO), but the majority of the content is written by an editorial team that is guided and advised by ASCO members. Clinical insights may be written by ASCO members, as well as other experts who wish to share their experiences with artificial intelligence. 

Who is Conexiant? 

The publisher of ASCO AI in Oncology. 

Who is the intended audience for ASCO AI in Oncology? 

ASCO AI in Oncology is designed for oncology clinicians, researchers, data scientists, bioinformaticians, health system leaders, and other professionals interested in the application of artificial intelligence across cancer care, research, and operations.

How does ASCO AI in Oncology itself use artificial intelligence? 

ASCO AI in Oncology uses artificial intelligence with human oversight to condense content for quick and easy reading and listening through newscasts, summarized articles, and more. Additionally, artificial intelligence was used to come up with this list of questions. 

How does ASCO AI in Oncology address bias and limitations in artificial intelligence?

The site covers known limitations, biases, and uncertainties associated with AI tools and highlights ongoing efforts to improve transparency, validation, and equity.

Will ASCO AI in Oncology have a publication?

No, content will remain digital only. 

Is content peer-reviewed?

Content is editorially reviewed but is not peer-reviewed.